Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Abraxis BioScience, a fully integrated biotechnology company, has announced that in connection with its strategic plan to spin-off Abraxis Health, it has named Lex Ploeg as its new senior vice president of integrative medicine and translational science.
Subscribe to our email newsletter
At Abraxis Health, Dr Ploeg will be responsible for building and integrating the company’s evidenced-based medicine capabilities, drug-discovery efforts and external partnerships that will serve as the foundation through which it will deliver personalized healthcare to patients.
Dr Ploeg has earned his MS degree in biochemistry from the University of Amsterdam and his PhD in biochemistry/enzymology/genetics from the University of Amsterdam/Netherlands Cancer Research Center.
Patrick Soon-Shiong, chairman and CEO of Abraxis BioScience, said: “Dr Ploeg joins Abraxis Health with a stellar business and academic pedigree and a profound interest in advancing patient access, compliance and care through vibrant research in new technologies and drug delivery methodologies. His passion and experience is well aligned with that of our growing team and we look forward to his many contributions as we seek to establish a new paradigm in medical care.”